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Abstract
In a medical setting, observational studies commonly involve patients who initiate
a particular treatment (e.g., medication therapy) and others who do not, and the goal
is to draw causal inferences about the effect of treatment on a time-to-event outcome.
A difficulty with such studies is that the notion of a treatment initiation time is not
well-defined for the control group. We propose an approach to estimate treatment
effects in longitudinal observational studies where treatment is given by indication and
thereby the exact timing of treatment is only observed for treated units. We present
a framework for conceptualizing an underlying randomized experiment in this setting
based on separating the process that governs the time of indication for treatment from
the mechanism that determines assignment to treatment versus control. Our approach
involves inferring the missing indication times followed by estimating treatment ef-
fects. This approach allows us to incorporate uncertainty about the missing times of
assignment, which induces uncertainty in both the selection of the control group and
the measurement of time-to-event outcomes for these controls. We demonstrate our
approach to study the effects on mortality of inappropriately prescribing phosphodi-
esterase type 5 inhibitors (PDE5Is), a medication contraindicated for certain types of
pulmonary hypertension, using data from the Veterans Affairs (VA) health care system.
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1 Introduction
In certain observational studies, particularly in a medical context, interest centers on esti-
mating the causal effects of an action, treatment, or intervention on a time-to-event outcome
(e.g., the effects of surgery on post-operative survival time). Insights about the effects of
these non-randomized treatments have the potential to help answer important questions
both in population health and in individualized medicine. In these settings, measuring time-
to-event outcomes in a treated group is straightforward; time is measured from treatment
initiation. However, a key obstacle for inference is the lack of observed initiation times in
the control group, without which a time-to-event outcome is not defined.
The question of how to make valid causal inferences in this setting using longitudinal,
observational data becomes further complicated with the possibility of confounding due to
“treatment by indication” (Poses et al., 1995). This issue stems from the principle that a
good clinician will initiate a new treatment only when evidence exists that the candidate
treatment is medically necessary for the patient in question (Poses et al., 1995). In studies
evaluating the effects of a non-randomized treatment on a population with a common disease
or condition, this means that treatment is initiated (and, therefore, assignment to treatment
is observed) only when the potential benefits outweigh the anticipated risks or side effects
associated with treatment. As a result, subjects who receive treatment during the study
period may differ systematically from untreated subjects observed during the same time
period in terms of their prognosis. This type of confounding can generally be avoided by
comparing groups of subjects who presented with similar indications at similar times after
their initial diagnosis; however, these variables are typically not recorded for subjects who
do not receive treatment. This issue is especially common in studies that rely on data
from electronic medical records, administrative databases, and health registries (Byar, 1980;
Levine and Julian, 2008; Freidlin and Korn, 2012). Thus, for the group of untreated subjects,
it is unclear whether treatment was indicated at an unknown time during the study and was
purposefully withheld at that time or if treatment was simply never considered due to lack of
indications. A primary challenge in this domain therefore concerns how to infer the unknown
indication times from the observed data.
In this paper, we consider how to draw causal inferences about a binary treatment, which
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can either be initiated or withheld from a given subject at a single point in time. This time
point, which we refer to as the “indication time”, is the time at which a subject presents with
a particular set of symptoms or pre-specified indications that necessitate clinical interven-
tion. The indication time for any individual might be a function of the subject’s behavior
(e.g., when a subject requests a medication therapy), or might be solely determined by
clinical factors. For instance, in our applied example, we consider a population of patients
in the VA health system who are diagnosed with certain types of pulmonary hypertension
(PH), where individuals may receive medication therapy in the form of phosphodiesterase-5-
inhibitors (PDE5Is) for treatment of PH-related symptoms only when it is determined that
the medication may be beneficial given the severity of the patient’s condition. As a result,
indication times may vary greatly across patients in a sample, which induces a complicated
time structure in the observed data. To accommodate this structure when attempting to
draw causal inferences, researchers often focus on estimands that are defined relative to a
time-varying treatment (e.g., the effect of initiating treatment now versus later). We pro-
pose an approach for treatment effect estimation that views indication times as a fixed but
possibly unknown pre-treatment covariate (i.e., a variable that is unaffected by assignment
to treatment or control) representing relevant characteristics related to the patient’s health.
We then condition on these indication times to construct an estimator of the causal effect of
treatment versus control that is independent from the time-structure of the underlying data.
The paper proceeds as follows. In Section 2, we first review existing methods in this
domain and describe a general strategy for making causal inferences in longitudinal ob-
servational studies by approximating a sequence of randomized trials. We then present
an alternative conceptualization of the data-generating process that can facilitate causal
inference in this setting, which is based on separating the process that governs the time of
indication for treatment from the mechanism that determines the receipt of treatment versus
control. In Section 3, we present a framework for designing longitudinal observational stud-
ies to approximate a hypothetical randomized experiment based on this conceptualization
and describe the formal assumptions required for inference. The core of this framework is a
joint state-space model for predicting indication times as a function of longitudinal covari-
ates, described in Section 4, which we use to infer the missing indication times for untreated
patients. In this Section, we also propose an approach for estimating treatment effects that
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directly incorporates uncertainty about the inferred indication times. We then illustrate the
proposed framework in Section 5 to study the effects of prescribing contraindicated PDE5Is
for treatment of PH using data from the VA health care system.
2 Background
When attempting to draw causal inferences in observational studies, it is desirable to “de-
sign” the study in a manner that approximates a randomized experiment (Rubin, 1984).
While this design-based approach to covariate adjustment in observational studies has been
widely applied to estimate causal effects using cross-sectional data, little work has focused on
extending these methods to longitudinal settings. In fact, how to properly design and ana-
lyze longitudinal studies of non-randomized medical interventions (comparative effectiveness
studies) remains a point of controversy (Rubin, 2010). A primary concern in this domain is
related to the lack of a well-defined control intervention (Huitfeldt et al., 2015). For instance,
in a study evaluating the efficacy of a particular medication, drug A, for treating depression,
initiation of control might be marked by the receipt of an alternative medication, drug B.
Alternatively, if the control intervention is defined as the decision to withhold drug A in
favor of a non-pharmacological approach (e.g., self-care or psychotherapy), then receipt of
assignment to control may not be available in the observed data. In these settings, unknown
values of treatment assignment may be missing due to measurement errors (e.g., if receipt of
the control intervention is not recorded) or may be (right-)censored due to follow-up (e.g., for
patients whose assignment occurs after the study has ended). When criteria for determining
indications for treatment cannot be applied to the pool of potential controls, an indication
time must be inferred for these units.
In many observational studies, controls are selected based on their similarity to treated
units with respect to pre-treatment variables observed during a baseline period. However,
control group selection becomes complicated in longitudinal settings where units may enter
the study at different points in calendar time. Instead of having a single baseline period for
all units, in this setting we observe a (potentially unique) baseline period for each treated
unit, defined as the time from study entry to the time of treatment initiation. The primary
challenge is then how to define a comparable pre-treatment period for potential controls
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who do not receive treatment at any point during the study window (Basse et al., 2016). To
address this issue, some studies have attempted to identify alternative indication times (i.e.,
“phantom” treatment times) for untreated units for whom there is no receipt of treatment.
For instance, in an observational study evaluating the effects of selective cyclo-oxygenase-2
inhibitors for treatment of upper gastrointestinal hemorrhage in eldery patients, Mamdani
et al. (2002) randomly assigned indication times for untreated units. Zhou et al. (2005)
proposed a similar approach for prescription time-distribution matching, whereby indication
times for each untreated unit are selected at random from the distribution of indication
times observed among the treated units. This strategy ensures that the treatment and
control groups will be balanced with respect to time of treatment initiation, but requires the
strong assumption that indication times are independent and identically distributed for all
units in the study population.
Other studies have addressed this issue by identifying a proxy for the time of treatment
indication (e.g., dispensement dates of other prescription medications during the study pe-
riod)(McGettigan and Henry, 2006). This approach is the basis of the “active-comparator
design” (Yoshida et al., 2015), which restricts the control group to the set of untreated units
who received another active drug during the study period. The core idea of this design is
that any given sample of untreated units is likely to include subjects with no indications for
treatment (e.g., mild disease) as well as subjects with contraindications for the treatment
of interest (e.g., due to severe coexisting conditions). While this framework provides a use-
ful template for designing comparative effectiveness studies, if the treatment of interest is
the most commonly used therapy for a given condition (i.e., a first-line therapy) and the
alternatives are used infrequently, selecting an active comparator can be challenging.
Other methods that attempt to address these issues are based on the assumption that,
with a sufficient follow-up period, all subjects will receive the treatment of interest (van
Houwelingen and Putter, 2011). Under this assumption, an alternative strategy for estimat-
ing causal effects is based on framing the data-generating process in terms of a sequence of
randomized experiments occurring over time, where at each time the treatment can either
be initiated or withheld (Robins et al., 2000; Herna´n et al., 2008). One approach based on
this framework is so-called risk set matching (RSM), a technique that was first proposed
in Li et al. (2001) and has since been widely used in practice (e.g., Danaei et al., 2013;
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Kennedy et al., 2010; Watson et al., 2019). Risk set matching aims to assess the effects of
different treatment sequences on an outcome observed at a fixed end-point, thereby avoid-
ing the issue of control group identification. Here, the implicit assumption is that, unlike
in a classical randomized experiment, all patients will receive treatment eventually and it
is rather their times of treatment that are a result of randomization. Accordingly, causal
effects are defined at each of a set of discrete time points and can be estimated by comparing
units who received treatment at that time with units who were not yet treated at that point.
The resulting inferences may be useful to practitioners interested in estimating the effects
of delaying treatment with a particular treatment and may help answer questions about the
optimal time to apply a medical intervention for patients that require treatment. However,
the resulting inferences may not be appropriate in settings with treatment by indication,
where the time of initiation is not under the control of the treatment initiator, usually the
clinician. When a patient presents with symptoms that indicate the need for medical in-
tervention, their health care provider is faced with a decision about which among available
treatments to initiate at that time. In these settings, it is not sensible to hypothesize about
how a patient’s outcomes would change if their indications had presented at a different time
(Angrist et al., 1996). Rather, the time of indication for treatment should be viewed as a
fixed pre-treatment covariate that characterizes the severity of the underlying condition, and
causal effects should be framed as contrasts of the outcomes that would be observed for each
unit under different treatment strategies initiated at that time.
3 A causal effects framework
The framework we propose mimics the protocol typically used to analyze data from a ran-
domized controlled trial, where outcomes are observed during a pre-specified follow-up period
beginning at the time of randomization, which is precisely the same time as initiation of ther-
apy. To motivate this framework, consider the following hypothetical randomized experiment
with a binary treatment, where interest is in estimating the causal effects of treatment on a
time-to-event outcome for a particular patient population. Here, treatment is defined as the
decision to apply the intervention, and the control treatment is defined as the decision to
withhold the intervention. Assume that patients become eligible for inclusion in the exper-
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iment only when their health reaches a point where clinical intervention may be beneficial
to the patient despite any associated risks or side effects (the so-called “indication time”).
Upon enrollment, suppose that patients are then randomized to receive either treatment or
control with probability that depends only on their indication time. After randomization,
suppose each patient is observed until the earliest occurrence of a pre-specified event (e.g.,
renal failure) or the end of follow-up, whichever occurs first. The primary outcome is based
on this event time calculated with respect to indication time. In this idealized experiment,
contrasts of outcomes between treated and control units with similar indication times will
be unbiased estimates of the causal effects of interest.
This conceptualization of the underlying randomized experiment explicitly defines the
control group as the set of untreated patients for whom treatment was indicated during the
study period and deliberately withheld (“true controls”). The remaining untreated patients
are those for whom no indications for treatment were present during the study (“ineligible
controls”). Because these patients are not assigned to treatment or control during the study
period, they are not relevant units for the purposes of causal inference. When indication
times are fully observed, the set of ineligible controls can easily be identified and discarded
prior to analysis. However, in many observational studies, indication times may be censored
due to follow-up or death and are often only partially observed, specifically, for only those
patients receiving treatment. In addition, the probabilities of assignment to treatment over
time are generally unknown and may be difficult to infer without expert domain knowledge.
3.1 Notation
We assume a cohort of N patients (i.e., observational study units), each of whom is observed
over a specified study time window divided into K discrete time periods. If a patient in
the cohort receives the treatment of interest during their observation period, then he or she
is included in the study as a treated unit. Other members of the cohort are eligible to be
controls during their respective observation periods.
For each unit i = 1, . . . , N , suppose we observe a vector of p covariate measurements
collected at the K time periods X i = (Xi0, . . . , XiK), where Xi0 is a p-vector of baseline
covariates observed at study entry. These covariates capture characteristics of each unit or
the unit’s environment (such as age, gender, physiological factors, diet, medical treatments,
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Table 1: Structure of the observed and missing data. ‘?’ denotes endogenous missingness
and ‘?’ denotes exogenous missingness.
Units Zi ∈ {0, 1} Ti ∈ {1, 2, . . .} Xi = (Xi1, . . . , XiTi) Yi(0)− Ti Yi(1)− Ti
1 1 t1 x1 ? y1 − t1
2 1 t2 x2 ? y2 − t2
3 ? ? ? y3−? ?
4 ? ? ? y4−? ?
and environmental exposures) over the course of the study. Let Ti denote the indication
time of unit i, which may occur at a discrete time within the study or may be censored at
the end of follow-up (i.e., Ti ∈ [0, K]∪ [K + 1, K + 2, . . .]). By construction, we assume that
units whose indication times are censored do not receive either treatment or control and we
let Si = 1{Ti ∈ [0, K]} be an indicator of eligibility for inclusion in the study as a control.
Similarly, let Mi be an indicator for the missingness of Ti with Mi = 1 for units whose
indication time is unobserved. Finally, let Zi be an indicator for assignment to treatment
upon indication for unit i, which equals 1 if unit i is assigned treatment at their indication
time Ti and equals 0 if unit i is assigned control upon indication. Unlike the classical setting
of a randomized experiment, suppose that Ti is only observed for units who are assigned to
treatment at indication times within the study period (i.e., when Zi = 1 and Ti ∈ [0, K]).
Table 1 shows the structure of the data in this setting. Here, it is important to dis-
tinguish between two distinct missing data mechanisms that give rise to the observed and
missing values. The first type of missing data are the indication times that are naturally
right-censored at the end of the study. Although, in principle, these values are observable
over a sufficient follow-up period, the missing-data mechanism is determined by the specified
observation period. Because missing data of this type are not “missing at random” (MAR;
Rubin, 1976), a model for the missing data mechanism must be incorporated into the anal-
ysis in order to yield valid causal inferences (Little and Rubin, 2019). The second type of
missingness in this setting is due to the fundamental problem of causal inference, which
states that we can observe at most one potential outcome (i.e., the potential outcome cor-
responding to the treatment actually received) for each subject in the study (Rubin, 1976).
These missing potential outcomes are therefore “endogenous” missing values in the sense
that the missingness mechanism is completely determined by treatment assignment. As in a
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standard randomized experiment, the unit-level missing potential outcomes are impossible
to observe under a given treatment assignment, and the goal of causal inference is therefore
to recover these values under plausible modeling assumptions in order to make inferences
about the causal effects of interest.
3.2 Causal estimands and assumptions for identification
Interest is in estimating the causal effects of assignment to treatment versus control on time-
to-event outcomes defined as the time from indication for treatment to the first occurrence
of an event of interest (e.g., death, hospital discharge, symptom remission). Under the
Rubin Causal Model (RCM; Holland, 1986), each participant has two potential outcomes,
Yi,Ti(0) and Yi,Ti(1), which represent the outcomes that would be observed for unit i under
assignment to control or treatment, respectively, where assignment occurs at exactly the
indication time Ti. Let YT (0) = (Y1T (0), . . . , YNT (0)) and YT (1) = (Y1T (1), . . . , YNT (1)), and
let YT = (YT (0), YT (1)) denote the complete set of potential outcomes for all units relative to
indication time T . We make the Stable Unit Treatment Value Assumption (SUTVA, Rubin,
1980), which asserts that there is no interference between units and no hidden forms of
treatment. Under this assumption, the average treatment effect (ATE) at a single indication
time T is defined as:
τT = E [YT (1)− YT (0)] ,
where E [·] is the average across all units. In longitudinal studies where indication may occur
over a fixed study period [0, K], we can construct an aggregate average measure of these
time-specific effects as
τ =
1
K
K∑
t=1
τt.
In settings where the outcome of interest Y is defined relative to a time of death or
failure, τ captures the average change in survival time under treatment compared to control
for units who present with indications for treatment at similar times over the study period.
Alternatively, as we will see in Section 5, causal estimands can also be specified to quantify the
average difference in survival rates at particular time points during the follow-up period. To
construct an unbiased estimator of τ using non-randomized data, we assume that treatment
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assignment is conditionally independent of the potential outcomes given all pre-treatment
covariates including the indication times (i.e., (Yi,Ti(0), Yi,Ti(1)) ⊥ Zi|XiTi , Ti). In the clinical
context we consider, this asserts that assignment to treatment versus control is unconfounded
given indication times, T , and observed pre-treatment covariates, X. Under this assumption,
an unbiased estimate of the treatment effect is:
τˆ =
1
N1
∑
i:Zi=1
YiTi(1)−
1
N0
∑
i:Zi=0
YiTi(0), (1)
whereN1 =
∑N
i=1 SiZi is the total number of treated units in the cohort andN0 =
∑N
i=1 Si(1−
Zi) is the total number of true controls. Here, in contrast to the classical setting, the out-
comes that are actually observed for each unit depend not only on their treatment assignment
but also on their indication time. For units whose indication times are not observed, these
missing times must be inferred in order to evaluate (1).. Note that with an untreated compar-
ison group, estimating the average treatment effect for the treated (ATT) using techniques
such as propensity score matching may be preferred, since we would rarely want to initiate
treatment for all units in the population. However, in the setting of treatment by indication
or when an active comparator is present (e.g., comparative effectiveness research), estimating
the average treatment effect for the entire population is desirable because we are focusing
on the choice of one treatment compared to another assuming that indications for treatment
have already occurred.
3.3 Overview of inferential approach
Our conceptual framework implies by design that the missingness of the times of indication,
Tmis, and the indicators for assignment to control, Z = 0, are completely dependent on the
values of those missing measurements. That is, we assume that the data (Ti, Zi) for unit i
will be missing if Ti > K (regardless of the value of Zi) or if Zi = 0 (regardless of the value
of Ti). This means that the missing measurements (indicated by Mi = 1) are “missing not
at random” (MNAR; Imbens and Rubin, 2015). By inferring the missing indication times
for the untreated units, we can minimize the information loss that arises from the missing
data mechanism to make more precise inferences from the observed data.
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The first goal is therefore to construct a model for predicting the observed indication times
T obs based on baseline and time-varying covariates X, which we will use to infer the missing
indication times. This model will also induce a probability distribution on the potential
outcomes in the control group, since the observed outcomes must be calculated relative to
the indication times. By applying the assumptions described above in Section 3.2, we can
separate the joint distribution of the complete data, including all observed potential outcomes
Y obsT as well as both the observed and unobserved indication times, T = (T
obs, Tmis) given
some global parameter θ partitioned as θ = (θ1, θ2, θ3) as
p(Y obsT , T, Z|X, θ) = p(Y obsT |T, Z,X, θ1)p(Z|T,X, θ2)p(T |X, θ3). (2)
For Bayesian inference with prior density p(θ) = p(θ1, θ2, θ3), the posterior density of θ given
the complete data is given by
p(θ|Y obsT , T, Z) ∝ p(Y obsT |T, Z,X, θ1)p(Z|T,X, θ2)p(T |X, θ3)p(θ1, θ2, θ3). (3)
Posterior inference on θ can then proceed by straightforward application of Markov Chain
Monte Carlo (MCMC) techniques, such as the Gibbs sampler (Geman and Geman, 1984;
Gelman et al., 2014). For example, in each iteration of the Gibbs sampler, we draw the
missing indication times Tmis from the conditional posterior predictive distribution of T obs
given covariates X and the current draw of the parameter θ.
The completed indication times can then be used to classify untreated patients into
distinct groups of true controls and ineligible controls based on eligibility S, where the true
control group consists of patients with Mi = 1 and Si = 1. For the true controls, we
can then calculate values for the potential outcomes YT (0) given the generated values of
T . These values are then regarded as observed potential outcomes, denoted Y obsT , which
are equal to the calculated YT (0) for units classified as true controls and equal to YT (1)
for treated units. Given the observed potential outcomes Y obsT , the completed times of
indication T = (T obs, Tmis) and the corresponding assignment vector Z, we can then update
the parameters θ1, θ2 and θ3 by drawing from the conditional posterior distribution,
p(θ1, θ2, θ3|Y obsT , T,X, Z) ∝ p(Y obsT |T, Z,X, θ1)p(Z|T,X, θ2)p(T |X, θ3)p(θ1, θ2, θ3). (4)
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Posterior inference on the causal effects of interest can be obtained by computing the
values of the constructed estimator within each MCMC iteration and summarizing their
distribution across the posterior sample. Thus, in each iteration, we can construct a dataset
consisting of the observed indication times, the simulated indication times, and all observed
potential outcomes, and use these completed data to calculate an estimate of the treatment
effect as in Equation (1). Alternatively, we could specify a joint distribution for the poten-
tial outcomes YT = (YT (0), YT (1)) that we could then use to impute the missing potential
outcomes Y misT in each iteration by drawing from the conditional distribution with density
function p(Y misT |Y obsT , T,X, θ). Repeating this process over many such simulated datasets
produces the approximate posterior distribution for all causal effects of interest. In the
same way, posterior samples of θ can provide posterior estimates of the parameters that
characterize the data-generating process; this is described in greater detail in Section 4.
4 State-space model for time of treatment indication
Based on the conceptual framework presented in Section 3, we propose a specific and prag-
matic model for predicting the time of indication for treatment - the earliest time at which
a patient presents with indications for clinical intervention - as a function of both fixed
and time-varying covariates. In particular, we hypothesize that observed covariate measure-
ments that reflect worsening health and diminished functional capacity will be predictive of
indication times. Similarly, we assume that covariates capturing provider characteristics or
temporal features (e.g., month or year when measurements are recorded) are independent of
the indication times but may influence the probability of assignment to treatment upon indi-
cation. For instance, in the application presented in Section 5, we expect the probability of
treatment to decline over time as clinicians become more informed about populations where
the medication of interest may be contraindicated. We capture these separate dependen-
cies through separate components of a hierarchical model; the first component characterizes
the stochastic process that governs patients’ indication times, and the second component
describes the conditional probability of assignment to treatment given the indication times.
Specifically, we model a patient-level health process generated by time-varying covariates
together with random fluctuations over time and adopt a so-called “threshold approach”
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(Albert and Chib, 1993), which views the indication time as the first hitting time of this
latent process. Similarly, we assume that the conditional probability of assignment to treat-
ment versus control given the indication time for each patient varies based on institutional
preferences, which may systematically change over time with widespread changes in the
established guidelines for treatment.
4.1 Model formulation
Suppose that the time series of covariate measurements for each unit, X i,1:K , is independent
from the measurements of other units, and let θi,1:K = (θi1, . . . , θiK) be a state variable
representing fluctuations in unit i’s overall health over the course of the study that are not
explained by the covariates. We assume a normal distribution for the daily health fluctuations
for unit i between time periods t and t− 1, such that
θit = ρθi,t−1 + it, it ∼ N (0, σ2 ), (5)
where N denotes the normal distribution. To make the model identifiable in our setting with
a binary observation process, we fix σ2 = 1. We assume |ρ| < 1 (i.e., the latent state process
θ1:T follows a stationary autoregressive model of order one). Thus, the model balances short-
term changes in health status with information from long-term health trajectories.
To initialize this process, we assume a standard normal prior distribution for θi0. Here,
the stochastic component it captures the unexplained variation of unit i’s health over time.
Conditional on the latent states θi,1:K , we then define the observation process Ψi,1:K , which
relates the overall health trajectory of unit i to their indication time according to a probit
regression model as
P (Ψit = 1|θit, Xit) = Φ(θit +Xitβ), (6)
where Φ(·) denotes the cumulative distribution function of a standard normal random vari-
able and β ∈ Rp is a vector of regression coefficients. Under the latent variable representation
of (5) and (6) (also referred to as a state-space mixed model; Czado and Song, 2008), the
indication time for each unit i can be expressed as
Ti = inf{t ∈ [0, K] : Ψit = 1}. (7)
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Thus, the model for indication times Ti induces a conditional distribution for the time
of indication given a vector of longitudinal, pre-treatment covariates. One of the main
advantages of this latent state representation is that it can flexibly accommodate both fixed
and time-varying covariates. The proposed modeling approach can also be extended to
settings with non-linear covariate effects by replacing the linear effects in (6) with nonlinear
contributions, such as those described in Denison et al. (2002).
We consider a separate model for the assignment mechanism, which determines assign-
ment to treatment versus control upon indication. Here, our model formulation is based
on the assumption that, in many settings, variation in treatment practices may be due to
clinician and/or institutional preferences rather than differences in patient characteristics
(Slaughter et al., 2017). In particular, we assume that each unit is assigned to treatment
with a probability that depends on their indication time. Conditional on Ti, and on ex-
ogenous covariates Di, the assignment mechanism for our specific model can be expressed
as
Zi|Ti, Di ∼ Bernoulli(piiT ), logit(piiT ) = δ0 + f(Ti, Di, δ1), (8)
where f(·) is a parameterized, possibly non-linear, function. deterministic transformation
of the indication time (e.g., calendar year or month). This model can be easily extended to
accommodate other artifacts of the study that are believed to influence the probability of
treatment assignment. For example, in Section 5, we let logit(piiT ) = δ0 + δ1Di where Di
is calendar time, and δ1 is restricted to be negative so that the probability of receiving the
treatment is monotonically decreasing over time.
4.2 Inferential procedure
Our procedure uses the Kalman Filter (Carlin and Polson, 1992) to marginalize out the latent
state parameters θ1:T for more efficient inferences. The full likelihood of the parameters
Ω = (Ψ1:K , ρ, β, δ0, δ1) can be written as
L(Ω) ∝
N∏
i=1
(
p(T obsi = t|Ω)p(Zi = 1|T obsi = t,Ω)
)1−Mi
(p(Mi = 0|Ω))Mi (9)
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where
p(Mi = 0|Ω) = 1−
K∑
t=0
p(Tmisi = t|Ω)p(Zi = 1|Tmisi = t,Ω).
Letting Z and M be the vectors of the Zi and Mi across the N patients, the associated
posterior density is therefore
p(Ω|T obs,Z,X,M ) ∝ p(Ω)
N∏
i=1
p(T obsi |X,Ω)p(Zi|T obsi ,Ω)p(Mi = 0|Ω).
Our modeling framework permits a flexible choice of prior distributions. For example, we
can assume a prior distribution that factors into independent densities as
p(Ω) = p(ρ, β, δ1, δ0,Ψ1:K)
= p(ρ)p(β)p(δ1)p(δ0)p(Ψ1:K |ρ, β).
Many distributional choices are possible for each prior component. One flexible set of choices
might be
p(ρ) ∼ N (ρ0, σρ) for −1 ≤ ρ ≤ 1
p(β) ∼ Np(β0,Σ0)
p(δ0) ∼ N (a, b)
p(δ1) ∼ Gamma(c, d) if δ1 is restricted to be positive
p(Ψ1:K |ρ, β) = p(Ψ1|ρ, β)
K∏
j=2
p(Ψj|Ψj−1, ρ, β)
Posterior sampling is straightforward to implement using standard software for imple-
menting MCMC methods such as JAGS (Plummer et al., 2003). Rather than sampling each
Ψt, t = 1, . . . , K, conditional on the rest, it is more efficient to sample them jointly via
MCMC using the Kalman filter (Carlin and Polson, 1992). As previously described, these
posterior samples allow us to measure the missing times of treatment assignment and assign-
ment to control according to (7), where Tmis > K for units with Ψ1:T = 0. Given the inferred
indication times, our framework implies that Zi = 0 for units with T
mis
i ∈ [0, K]. Recall
that treatment assignment is undefined for those whose time of treatment assignment was
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censored by the end of the study (i.e. units with Tmisi > K). Finally, we can calculate the
observed outcomes for units inferred to belong to the group of true controls by computing
the difference between the observed event times and the inferred indication times for those
units.
4.3 Bayesian analysis with inferred indication times
One of the benefits of the proposed approach is that it allows us to make inferences about
the missing indication times that are free from the outcome analysis. Our approach allows
for flexible specification of the causal estimands of interest and also allows researchers to
choose any mode of inference for analysis of the outcomes that they see appropriate. For
example, one might use the posterior mode of inferred times of indication for each unexposed
unit calculated over a large number of MCMC samples as the point estimate for that unit’s
indication time. This can then be viewed as a single imputation of the missing values, and
conditional on these estimates one could estimate the treatment effects by simple compar-
isons of means of the time-to-event outcomes (e.g., using a Neymanian or Fisherian mode of
inference). Alternatively, our framework also allows for more sophisticated analysis of out-
comes. For instance, we could first obtain a large number of posterior samples for the missing
times of indication across for all untreated units and use these samples to form unit-level
empirical posterior distributions of the missing indication times. Then, one might iteratively
impute values from these distributions and calculate the values of the corresponding observed
potential outcomes in each iteration. Contrasts between treatment and control groups eval-
uated across all iterations would then produce a distribution for the causal estimate (given
the potential outcomes) that incorporates uncertainty about the missing indication times.
It is important to note is that this type of approach is only partially Bayesian in that we
are using Bayesian methods to infer missing values that are needed in order to measure the
observed outcomes. To make this a fully Bayesian approach, as previously mentioned, one
could also specify a model for the missing potential outcomes (i.e., the missing time-to-event
outcomes under alternative assignment) conditional on the partially observed outcomes, the
assignment vector, and/or the covariates.
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5 Application
To illustrate our proposed methods, we analyzed data from a recent study using electronic
medical records from the VA health system evaluating the impacts of inappropriate prescrib-
ing practices for the treatment of pulmonary hypertension (Kim et al., 2018). Pulmonary
hypertension is a condition of high blood pressure that affects arteries in the lungs and heart.
One common treatment for PH is a class of medications called phosphodiesterase-5-inhibitors
(PDE5Is), which act on enzymes causing blood vessels to relax in order to lower blood pres-
sure. While PDE5Is have been shown to be effective for treating some rare forms of PH,
Freiman et al. (2015) identified the use of these drugs as wasteful, ineffective, and potentially
harmful for treating patients with more common types of PH caused by left heart disease
(WHO Group 2) or hypoxemic lung disease (WHO Group 3). Despite its contraindication, a
study of veterans diagnosed with these types of PH over the years of 2005 to 2012 identified
over 2,000 prescriptions for PDE5Is that were inappropriately administered to patients in
the VA health system. To understand the impact of these inappropriate treatment practices
on patient outcomes, it is of interest to measure the causal effects of prescribing PDE5Is to
patients with PH Groups 2 and 3 on the time lag between the application of the intervention
and the occurrence of a clinical event of interest (e.g., time from treatment to death).
The primary question that we sought to address through this analysis concerned the
extent to which treatment with PDE5Is for patients diagnosed with PH Groups 2 and 3
impacted the one-year survival rate compared to patients who had similar indications for
treatment but were not prescribed PDE5Is during the study period. As a secondary ob-
jective, we were also interested in inferring which among a large set of observed patient
and provider characteristics were strongly associated with an increased risk of receiving a
contraindicated PDE5I for treatment of PH.
5.1 Data
Our data set contains demographic and laboratory measurements as well as records of the
utilization of medications, inpatient and outpatient services for over 350,000 veterans who
were diagnosed with PH Groups 2 and 3 and received prescription medications from the VA
from 2005 to 2016. For all patients, baseline health-related measurements were collected at
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the time of first PH diagnosis based on ICD-9 diagnosis codes within either the VA health
system or Medicare. Subsequent health-related measurements were collected at intermittent
observation times corresponding to patient-provider clinical interactions (e.g., an inpatient
or outpatient visit). The exact number of measurements recorded and the time elapsed
between subsequent measurements varied by patient. Observations with implausible values
for lab measurements or demographic variables were excluded prior to analysis.
For the present analysis, we considered patients who at the time of PH diagnosis (Group
2 or 3) were between 65 to 95 years of age, were eligible for Medicare benefits, and who had
not received prescriptions for a PDE5I medication prior to PH diagnosis. Because female
patients comprised less than 3% of the patient population who met these initial eligibility
criteria, we further limited our analysis to only male patients. For data integrity purposes,
we also excluded any patients who were receiving Medicare part C at the time of diagnosis
as well as patients who did not fill any prescriptions within the VA health system during
the one year prior to their diagnosis, since these patients may have received PH related
care from private providers that we could not track. Finally, we excluded any patients who
received a prescription for nitrates after PH diagnosis and prior to a PDE5I prescription
because nitrates are contraindicated for treatment with PDE5Is. Among patients who met
all initial eligibility criteria, we defined the “treatment group” as the set of patients who
filled at least one prescription during the study period for a PDE5I medication primarily
indicated for the treatment of PH. In particular, we excluded medications with secondary or
off-label indications for the treatment of PH such as sildenafil, tadalafil, and verdenafil.
Because we observed the prescription dispense dates rather than the dates when the
medications were first prescribed, we excluded from our analyses any treated patient whose
first PDE5I prescription was dispensed more than 60 days after a hospital visit. After
applying all exclusion restrictions, the remaining sample was comprised of 534 patients who
received treatment for PH with a PDE5I medication within a one-year period following
their diagnosis date and 167,701 potential controls who did not receive a PDE5I during
that period. Our outcome of interest is survival time in the period following indication
for treatment, which we observed for treated units and must be inferred for units in the
control group. We consider the date of PH diagnosis as the time of “earliest eligibility”
for indication. For each potential control patient, we base our inferences on clinical data
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observed at intermittent intervals from the time of earliest eligibility until death or the end
of follow-up in December 2016, whichever occurred first.
5.2 Constructing comparison groups and time-varying covariates
To make the assumptions of our proposed framework described in Section 3 more plausible
in this setting, we selected a set of potential control units who appeared similar to the
treatment group at baseline based on health-related measurements collected in the 1 year
prior to PH diagnosis (excluding the date of diagnosis). We considered a set of 17 baseline
covariates identified as predictive of the time of assignment to treatment within the treatment
group. See Appendix A for details of this variable selection procedure. Potential controls
were selected using 1:1 nearest-neighbor matching with replacement (Rubin, 1973), whereby
each treated unit is matched to its closest control unit based on the Mahalanobis distance
calculated over baseline covariates.
This produced a final sample of 534 treated units and 531 matched control units who
were similar to the treatment group at their times of PH diagnosis but did not receive a
PDE5I at any point during the observation period. Diagnostics performed after matching
confirmed that the covariate distributions were adequately balanced between the treatment
group and the matched potential control group. Table 2 shows descriptive statistics on
baseline variable for the final matched samples. After matching, we proceeded under the
assumption that overall health status was unconfounded given baseline covariates such that
patients with similar covariates at baseline were expected to have similar health trajectories
and therefore, similar indication times over the course of study.
In addition to baseline covariates, we also included in our analyses a number of time-
varying covariates collected at intermittent observation times throughout the study period.
Specifically, we considered six time-varying, clinically meaningful covariates that indicate
changes in patients’ disease severity and health status over time, including an indicator for
whether the patient was most recently observed in an outpatient versus inpatient setting, an
indicator for the presence of new comorbidities, and separate indicators for recent hospital-
ization, organ failure events, cardiac events or pulmonary procedures recorded during the 30
days prior to each visit. We also included as a single time-varying covariate the Mahalanobis
distance calculated between each patient’s laboratory measurements (e.g., heart rate and
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Table 2: Baseline covariate data for potential controls and treatment group.
Potential Control Treatment
PH Group 2 88% 88%
Recently Hospitalized 13% 12%
Recent Procedure 65% 75%
Recent ER Visit 52% 53%
Age 74.8 74.5
Weight 203.3 204.5
Height 69.5 69.5
Resting Heart Rate 74.2 75.1
Systolic Blood Pressure 130.1 130.5
Diastolic Blood Pressure 71.2 71.2
Inpatient Days 1.19 1.22
Outpatient Days 27.3 27.9
Number of Comorbidities 0.52 0.54
Cardiac Events 1.60 1.49
Pulmonary Events 0.61 0.69
Organ Failure Events 1.09 1.16
Number of Medications 11.4 11.8
blood pressure) at baseline and values of the same laboratory variables collected at each
follow-up visit. This allowed us to greatly reduce the dimension of the covariate space and
operationalize the laboratory variables in terms of gain scores.
We observed a strong positive correlation between the empirical probabilities of survival
and indication times for patients in the treatment group. Among 77 patients who received
treatment within 7 days following their PH diagnosis (i.e., patients with Ti ≤ 7), only
53 patients (68.8%) were alive one year post-diagnosis. Averaged over all 534 patients
whose indication times occurred within one year of diagnosis (i.e., the treatment group),
this survival rate increased to 80.6%. In contrast, the survival rate at one-year after PH
diagnosis for the 531 matched potential controls was approximately 81.7%; however, because
we do not observe the indication times for these patients, this is a naive estimate that is likely
negatively biased. Also note that these survival probabilities are defined relative to diagnosis
times, which we regard as a fixed pre-treatment covariate. As a result, these measurements
are purely descriptive and should not be regarded as treatment effects.
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5.3 Results
Using the approach described in Section 3, we fit the model defined by equations (5)–(8)
using MCMC posterior simulation. We constrained δ1, the effect of calendar time on the log-
odds of PDE5I initiation, to be negative for this application since the probability of receiving
PDE5Is was believed to be monotonically decreasing over the course of the study. This is
because PDE5Is were believed to be the standard, first-line therapy for treatment of PH at
the beginning of the study with use steadily decreasing as knowledge of its contraindication
for some PH patients spread throughout the medical community.
To estimate the treatment effects of interest, we fit eight distinct models. Each model
assumed differing time windows within which the indication time might occur, or that (for
some untreated units) the indication time occurred beyond the time window. Specifically,
we assumed time windows corresponding to indication times occurring within the first 14
days, 30 days, 60 days, 90 days, 120 days, 180 days, 270 days, and 365 days (1 year) after PH
diagnosis. Our health process model component assumed that changes could occur daily, so
that the number of time periods K varied from 14 to 365. For each interval, we estimated the
average causal effects of treatment versus control on a binary measure of survival at follow-up
one year after indication. In addition, we estimated the conditional average treatment effect
(CATE) for each of the eight time intervals, where in each interval the average is over the
subset of patients whose indication times were within a specified range (e.g., the conditional
average treatment effect for patients whose indication times occurred within 15-30 days
following PH diagnosis). To estimate these effects, we first identified the subset of units
whose indication times (either observed or inferred) were within the specified study period
based on the current values sampled using MCMC. Within this subset, we then calculated
survival rates at one year post-indication for treated units as well as for units classified as
true controls. Finally, we measured the treatment effect as the difference between these
two proportions. For each of the specified study periods, we ran the MCMC sampler with
four parallel chains each run for 20,000 iterations, where the first 5,000 draws of each chain
were discarded as a burn-in period. With the resulting 60,000 samples, we calculated the
posterior means and 95% credible intervals (CI) for all model parameters. In all cases,
the MCMC simulated model parameters and quantities of interest raised no concerns using
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Table 3: Posterior median number of true control units inferred from matched sample of
potential controls at each time point and estimated effects of treatment compared to control
with 95% posterior intervals.
Study Number Inferred number One-year survival Estimated impact
period treated of “true controls” after indication of PDE5I
(K) (N1) Nˆ0K 95% CI Treatment Control τˆK 95% CI
14 Days 109 48 (34, 62) 71.6% 82.0% -10.4% (-18.6%, -1.6%)
30 Days 164 88 (72, 103) 73.2% 82.8% -9.6% (-14.5%, -3.8%)
60 Days 233 113 (96, 127) 75.1% 83.3% -8.2% (-12.8%, -5.0%)
90 Days 280 127 (111, 141) 72.5% 83.3% -10.8% (-14.7%, -6.8%)
120 Days 318 134 (119, 147) 73.0% 85.1% -10.1% (-14.1%, -6.4%)
180 Days 380 150 (135, 162) 73.6% 84.3% -11.0% (-14.1%, -7.5%)
270 Days 456 165 (151, 180) 74.0% 84.5% -10.5% (-13.9%, -7.5%)
365 Days 534 183 (170, 195) 72.5% 84.5% -12.0% (-14.6%, -9.8%)
standard diagnostics including those by Geweke (1992) and Gelman et al. (1992). As an
additional sensitivity check, we evaluated the performance of the proposed model in each
setting under different choices of hyperparameters using the deviance information criterion
(DIC; Spiegelhalter et al., 2002) and found the results to be generally unaffected.
Posterior means and 95% credible intervals for the treatment effects of interest are pre-
sented in Table 3. Here, the causal estimand at each time point is defined as the average
effect of treatment on one-year survival for all patients with indication times occurring at or
before that time (i.e., τˆK = E[Yi(1)−Yi(0)|Ti ≤ K] for K = 14, 30, 60, 90, 120, 180, 270, 365).
Table 3 also summarizes the cumulative number of potential control units identified as “true
controls” at each time point based on the posterior median of the 60,000 MCMC samples
(i.e., Nˆ0K =
∑
Zi=0
1{Tˆi ≤ K}). Figure 1 shows the smoothed effects of treatment over a
one year period following PH diagnosis, calculated using a cubic smoothing spline (Marsh
and Cormier, 2001), which we specified with eight knots located at each posterior mean
treatment effect estimated using our model.
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Figure 1: Cubing smoothing spline curve for estimated effects of PDE5I compared to control
on one-year survival rate based on time from diagnosis to indication. Shaded area shows
pointwise 95% posterior credible interval.
These results suggest that the majority of the matched potential controls were ineligible
to receive treatment during the one year period following their PH diagnosis. For these
patients, lack of treatment can therefore be interpreted as a lack of indication for treatment.
On the other hand, potential controls with inferred indication times occurring at or before
each specified time point are regarded as “true controls” for whom, upon indication for
treatment, PDE5Is were actively withheld, possibly in favor of alternative medication or
treatment strategy. Given the inferred times of indication, these patients provide a credible
comparison group with which we can make causal inferences. In particular, our findings
indicate that among patients with PH (Groups 2 and 3) who are indicated for treatment
at any point in the one year following their diagnosis, treatment with PDE5Is has a large,
negative effect on one-year survival probability.
Table 4 shows posterior estimates for the baseline and time-varying covariate effects, β1
and β2, as well as for the correlation between patients’ latent health states, ρ, and parameters
governing the probability of assignment to treatment upon indication, δ0 and δ1. Here again,
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our results are largely consistent across the settings with credible intervals shrinking as study
period widens. In general we find a small negative posterior correlation between latent health
measurements, which decreases in magnitude over time. This suggests there may be some
variation in patients’ overall health that is not explained by the observed covariates in the
time period immediately following PH diagnosis, but this systematic variation dissipates over
time.
Posterior estimates for parameters of the treatment assignment mechanism are also rel-
atively stable across the different study periods. Baseline probabilities of treatment upon
indication range from 0.79 for the study period of 14 days to 0.73 for the study period of
365 days, with the probability of treatment slowly decreasing over time. Figure 2 shows
this trend over time for eligible patients in the VA health care system diagnosed with PH
between 2002 and 2016 based on posterior median estimates of δ0 and δ1 within each study
period.
A key feature of our model is that it allows us to directly evaluate which of the baseline and
time-varying covariates carry more or less information about patients’ times of indication. In
the present study, posterior inferences for covariate effects within each of the study periods
were similar. In general, our findings suggest that patients with PH Group 2 were more
likely to have indications for treatment shortly after PH diagnosis than patients with PH
Group 3. Results also indicate that occurrence of one or more incidental medical procedures
(e.g., cardiac surgery or pulmonary function testing) within 30 days prior to PH diagnosis
is strongly associated with earlier indication times. Further, we found that patients who
regularly receive care in an inpatient setting generally have earlier indication times than
patients whose follow-up visit typically occur in an outpatient setting. Among the other
baseline covariates included in our analysis, occurrence of one or more pulmonary disease
events (e.g., pneumonia) within 30 days prior to PH diagnosis and number of comorbidities
present at baseline were also positively associated with indication for treatment during the
study period. These results may offer insights for clinicians about best practices for health
management of PH patients, and may also be used to guide modeling decisions in other
applications.
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Figure 2: Cubic smoothing spline curves showing the conditional probability of receiving
PDE5I based on time of indication for eligible patients in the VA health care system diag-
nosed with PH between 2002 and 2016. Dashed lines show 95% posterior credible intervals.
5.4 Comparison with inferences based on risk set matching
Risk set matching (RSM) serves as a useful reference for examining the relative performance
of our proposed approach. Table 5 presents the one-year post-indication survival rates within
the treatment and control groups, where controls are identified using risk-set matching. Here,
26
for each treated patient with observed indication time t, we identified the not-yet-treated
patient that was most similar in terms of their probability of receiving treatment based on
covariates observed up to time t.
Table 5: One-year survival rates following treatment indication for treated patients and
controls identified using risk set matching
Study One-year survival Estimated
period after indication impact
Treatment Matched Control of PDE5I
14 Days 71.5% 71.5% 0.0%
30 Days 73.2% 73.6% -0.5%
60 Days 75.1% 76.7% -1.6%
90 Days 72.5% 76.9% -4.4%
120 Days 73.0% 77.4% -4.4%
180 Days 73.6% 77.7% -4.1%
270 Days 74.0% 77.1% -3.3%
365 Days 72.5% 75.8% -3.1%
These findings generally agree with the results previously described. In general, we find
that estimates obtained using RSM are systematically smaller in magnitude than results
based on the proposed approach. However, because these estimates reflect the average
effect of treatment on the treated rather than the average treatment effect across the entire
patient population, these differences are not surprising. In particular, estimates calculated
using RSM reflect the effects of delaying treatment with PDE5Is for the subset of patients
that have indications for treatment during the study period. This means that for each
study period, patients treated with PDE5Is during that period are compared to a matched
control group consisting of patients who had not yet received treatment at that point but
may have received treatment at a later point in the study. The main differences between
the two approaches therefore lays in the interpretation of the parameters. Where the model
proposed in Section 4 yields an estimate that captures the impact of assignment to treatment
versus control at time t on one-year survival for all individuals in the population who had
indications for treatment at that time, inferences based on RSM yield an estimate of the one-
year survival rate for individuals who were indicated versus not yet indicated for treatment
at time t given the confounders measured up to that time.
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6 Discussion
In this paper, we propose a novel conceptualization of longitudinal observational studies with
treatment by indication and provide a template for the design and analysis of such studies
in a manner that approximates a randomized experiment with a binary treatment. This
conceptualization reformulates the problem of evaluating a time-varying treatment in the
presence of time-varying confounders as one of evaluating a binary treatment administered
at a fixed time point, where the time of assignment is a partially observed pre-treatment
confounder. Our hope is that this simplified representation of a traditionally complex data
structure will allow for more straightforward analyses of health data in the digital age (e.g.,
data from electronic medical records).
The merit of the proposed model is that it allows for model-based assessments of the
times of treatment indication based on disease progression that can accommodate time-
varying covariates measured at intermittent observation times (i.e., when there is missing
data and/or substantial variation in the timing of patient-provider visits). Our approach
allows for systematic evaluation of the underlying health factors that may be most influential
in determining a patient’s need for treatment. Inferences based on this modeling strategy
may be useful to address a number of important questions in health services research - for
example, what preventative health strategies might be most effective for delaying the onset
of indications for treatment? The model also allows us to obtain conditional probabilities
for a subject having indications for treatment at different points over time, which could be
used to inform preventative treatment strategies. We note that the proposed model assumes
that subjects’ overall health fluctuates under natural conditions.
As described in Section 4, the proposed model for time of indication for treatment can
accommodate both fixed and time-varying covariates, which can be useful in explaining
differences in the aspects of health associated with subject-specific characteristics and/or
conditions that vary between hospital visit within a subject. Alternatively, covariate data
could be excluded entirely from the model to make inferences about indication times that
are viewed as fully stochastic. Another possibility for modeling variability in the parameters
involves the inclusion of provider-level, or geographic-specific random effects. However, this
complicates the evaluation of the likelihood, rendering model fitting more challenging.
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Finally, we note that our application and inferential results should be regarded as an
illustrative example of the proposed methods rather than an attempt to provide definitive
answers about the causal effects of inappropriate prescribing practices on health-related out-
comes for PH patients. In particular, for researchers interested in drawing causal inferences
from observational studies with time-varying exposures, which often require a complex and
challenging design process that can obfuscate any resulting inferences, the conceptual frame-
work we present offers an alternative formulation of the underlying causal problem that is
both intuitive and relatively straightforward to implement. The proposed approach can also
be flexibly extended to accommodate a range of data structures, for instance in studies with
multivariate outcomes.
We believe the framework presented in this paper will help expand the scope and usability
of data from observational longitudinal studies and will facilitate investigation of these rich
data sources across a wide variety of disciplines. While our approach was developed in a
medical setting, the applicability is far more general and offers natural extensions for applied
research in education, psychopathology, and social science (see, e.g., Willett et al., 1998, for
a discussion of several longitudinal observational studies in these domains). For instance,
the methods described here could be used to engage with a longstanding debate in education
research concerning the impact of parental divorce on educational achievement for children
(e.g., Ayoub et al., 1999; Kim, 2011; Brand et al., 2019). When we define the individual-level
effect of a divorce on educational attainment, we are faced with a seemingly time-varying
treatment (i.e., a parental divorce can occur at many points in time throughout childhood)
and a time-to-event outcome (e.g., time to high school completion) (Brand and Xie, 2007).
Under the proposed framework, the time of indication for divorce could be conceptualized as
the first-hitting-time of a latent state process that represents marital stability. By inferring
the plausible times of indication for divorce for families who remained married during a given
study period, our approach could be used to obtain more precise estimates of the effects of the
decision to divorce on time to degree completion for individuals who experience family stress
and/or marital instability during childhood (Sun and Li, 2002). Our framework could also
be applied to study the causal effects of the decision to attend or stop attending a religious
service on the time to remission for depression (VanderWeele et al., 2016), or to estimate the
effects of income loss on all-cause mortality (Etches, 2009). The wide applicability of our
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approach, as illustrated by these several example observational studies, can help advance
our collective understanding of best practices in this important domain.
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A Covariate selection procedure for VA application
Covariate measurements were collected for each patient during each visit that occurred in the
study period, and each of the 534 treated patients in our analysis was observed for between
one to 611 distinct visits during the study period. For variable selection, we first constructed
a new dataset containing observations for each of the 534 treated patients at each of two
time periods: 1) the visit associated with assignment to treatment, and 2) the preceding
visit. Patients who received assignment to treatment at their first visit were included in the
dataset only once. Each observation vector in the resulting dataset therefore corresponds
to the covariate values of a patient who has not yet been assigned or to a patient at their
time of assignment. In principle, contrasts of covariates between these two groups should
capture information about how the latent health process - and the corresponding indication
for assignment to either treatment or control - varies with these longitudinal measurements.
For variable selection, we performed random forest analysis (Breiman, 2001) implemented
using the “randomForest” package in R (Breiman and Cutler, 2003) to evaluate the relative
importance of each of the time-varying covariates for predicting the time of indication for
treatment. Using this procedure, we identified the 20 most influential time-varying covariates
from over 150 available variables. Among these 20 covariates were several related to the
current physical characteristics of the patient (e.g., current weight and blood pressure) as
well as variables that captured changes in these physical measurements (e.g., change in
weight). Other important covariates include the number of comorbidities that the patient
has at the time of the visit and changes in health care utilization such as recent organ failure
events (e.g., right heart failure), recent inpatient visits, or receipt of incidental procedures
(e.g., echocardiograph).
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